<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Tumors of female reproductive system</journal-id><journal-title-group><journal-title xml:lang="en">Tumors of female reproductive system</journal-title><trans-title-group xml:lang="ru"><trans-title>Опухоли женской репродуктивной системы</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1994-4098</issn><issn publication-format="electronic">1999-8627</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1002</article-id><article-id pub-id-type="doi">10.17650/1994-4098-2022-18-3-107-111</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>GYNECOLOGY. REVIEWS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ГИНЕКОЛОГИЯ. ОБЗОРНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Molecular effects of Mastodynon: realities and prospects for cancer prevention</article-title><trans-title-group xml:lang="ru"><trans-title>Молекулярные эффекты препарата Мастодинон: реалии и перспективы для профилактики рака</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8814-636X</contrib-id><name-alternatives><name xml:lang="en"><surname>Vysotskaya</surname><given-names>I. V.</given-names></name><name xml:lang="ru"><surname>Высоцкая</surname><given-names>И. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Irina Viktorovna Vysotskaya </p><p><italic>Build. 2, 8 Trubetskaya St., Moscow 119991</italic></p></bio><bio xml:lang="ru"><p>Ирина Викторовна Высоцкая </p><p><italic>119991 Москва, ул. Трубецкая, 8, стр. 2</italic></p></bio><email>vysotskaya.irina@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4893-8770</contrib-id><name-alternatives><name xml:lang="en"><surname>Kim</surname><given-names>E. A.</given-names></name><name xml:lang="ru"><surname>Ким</surname><given-names>Е. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>Build. 2, 8 Trubetskaya St., Moscow 119991</italic></p></bio><bio xml:lang="ru"><p><italic>119991 Москва, ул. Трубецкая, 8, стр. 2</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0040-3136</contrib-id><name-alternatives><name xml:lang="en"><surname>Kirsanov</surname><given-names>V. Yu.</given-names></name><name xml:lang="ru"><surname>Кирсанов</surname><given-names>В. Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>Build. 2, 8 Trubetskaya St., Moscow 119991</italic></p></bio><bio xml:lang="ru"><p><italic>119991 Москва, ул. Трубецкая, 8, стр. 2</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3621-7394</contrib-id><name-alternatives><name xml:lang="en"><surname>Polikarpova</surname><given-names>S.  B.</given-names></name><name xml:lang="ru"><surname>Поликарпова</surname><given-names>С. Б.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>Build. 2, 8 Trubetskaya St., Moscow 119991</italic></p></bio><bio xml:lang="ru"><p><italic>119991 Москва, ул. Трубецкая, 8, стр. 2</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0153-3311</contrib-id><name-alternatives><name xml:lang="en"><surname>Ponomarev</surname><given-names>V. E. </given-names></name><name xml:lang="ru"><surname>Пономарев</surname><given-names>В. Е.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>Build. 2, 8 Trubetskaya St., Moscow 119991</italic></p></bio><bio xml:lang="ru"><p><italic>119991 Москва, ул. Трубецкая, 8, стр. 2</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">I. M. Sechenov First Moscow State Medical University, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Первый Московский государственный медицинский университет им. И. М. Сеченова» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-12-02" publication-format="electronic"><day>02</day><month>12</month><year>2022</year></pub-date><volume>18</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>107</fpage><lpage>111</lpage><history><date date-type="received" iso-8601-date="2022-12-02"><day>02</day><month>12</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-12-02"><day>02</day><month>12</month><year>2022</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://ojrs.abvpress.ru/ojrs/article/view/1002">https://ojrs.abvpress.ru/ojrs/article/view/1002</self-uri><abstract xml:lang="en"><p>The article presents updated data concerning the molecular mechanisms of influence of the well-known in clinical practice drug Mastodynon. The paper provides evidence of a significant effect of the compounds containing in its composition on the cell lines of a number of malignant neoplasms: breast cancer, hepatocellular carcinoma, leukemia and others. The data obtained are extremely attractive in the perspective of using the drug as a preventive agent.</p></abstract><trans-abstract xml:lang="ru"><p>В статье приводятся обновленные данные, касающиеся молекулярных механизмов влияния хорошо известного в клинической практике лекарственного препарата «мастодинон». Освещаются работы, свидетельствующие о значительном влиянии соединений, входящих в его состав, на клеточные линии ряда злокачественных новообразований: рака молочной железы, гепатоцеллюлярной карциномы, лейкемии и др. Полученные данные являются чрезвычайно привлекательными в перспективе использования препарата в качестве профилактического агента.</p></trans-abstract><kwd-group xml:lang="en"><kwd>cancer prevention</kwd><kwd>angiogenesis</kwd><kwd>apoptosis</kwd><kwd>molecular effects</kwd><kwd>Vitex agnus-castus</kwd><kwd>chasteberry</kwd><kwd>casticin</kwd><kwd>Mastodynon</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>профилактика рака</kwd><kwd>ангиогенез</kwd><kwd>апоптоз</kwd><kwd>молекулярные эффекты</kwd><kwd>Витекс священный</kwd><kwd>прутняк</kwd><kwd>кастицин</kwd><kwd>мастодинон</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Global website of the World Health Organization. Available at: https://www.who.int/en</mixed-citation><mixed-citation xml:lang="ru">Глобальный сайт Всемирной организации здравоохранения. Доступно по: https://www.who.int/ru</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><mixed-citation>Sasaki Y., Takagi K., Akashira J.-I. et al. Immunolocalisation or estrogen-producing and metabolizing enzymes in bening breast disease: comparison with normal breast and breast сarcinoma. JCA 2010;101(10):2286–92. DOI: 10.1111/j.1349-7006.2010.01673.x</mixed-citation></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Kogan I.Yu. Mastopathy, new approaches to diagnostics and pathogenetic therapy. Journal of Zhurnal akusherstva i zheskikh bolezney = Obstetrics and Women’s Diseases 2010;LIX(1):66–70. (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Коган И.Ю. Мастопатия: новые подходы к диагностике и патогенетической терапии. Журнал акушерства и женских болезней 2010;LIX(1):66–70.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><mixed-citation>Madaus G. Lehrbuch der biologischen Heilmittel. 4 Bände. Thieme, Leipzig, 1938.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Panay N. Guidelines on Premenstrual Syndrome. The National Association for Premenstrual Syndrome (NAPS), 2016. Available at: http://www.pms.org.uk/assets/files/guidelinesfinal60210.pdf</mixed-citation></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Vysotskaya I.V., Letyagin V.P., Cherenkov V.G. et al. Clinical recommendations of the Russian Society of oncomammologists for the prevention of breast cancer, differential diagnosis, treatment of precancerous and benign diseases of the mammary glands. Opukholi zhenskoy reproduktivnoy systemy = Tumors of female reproductive system 2016;3(12):43–52. (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Высоцкая И.В., Летягин В.П., Черенков В.Г. и др. Клинические рекомендации Российского общества онкомаммологов по профилактике рака молочной железы, дифференциальной диагностике, лечению предопухолевых и доброкачественных заболеваний молочных желез. Опухоли женской репродуктивной системы 2016;3(12):43–52.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Vysotskaya I.V., Letyagin V.P. Benign diseases of the mammary glands. 2nd edn. Moscow: SIMK, 2019. 103 p. (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Высоцкая И.В., Летягин В.П. Доброкачественные заболевания молочных желез. 2-е изд-e. М.: СИМК, 2019. 103 с.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Benign Dysplasia of the Mammary Gland. Clinical Recommendations of the Ministry of Health of Russia, 2020. Available at: http://cr.rosminzdrav.ru/#!/schema/1027. (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Доброкачественная дисплазия молочной железы. Клинические рекомендации Министерства здравоохранения РФ, 2020 г. Доступно по: http://cr.rosminzdrav.ru/#!/schema/1027.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><mixed-citation>Zhou Y., Tian L., Long L. et al. Casticin potentiates TRAIL-induced apoptosis of gastric cancer cells through endoplasmic reticulum stress. PLoS One 2013;8(3):e58855. DOI: 10.1371/journal.pone.0058855</mixed-citation></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Zhou Y., Peng Y., Mao Q.Q. et al. Casticin induces caspase-mediated apoptosis via activation of mitochondrial pathway and upregulation of DR5 in human lung cancer cells. Asian Pac J Trop Med 2013;6(5): 372–8. DOI: 10.1016/S1995-7645(13)60041-3</mixed-citation><mixed-citation xml:lang="ru">Zhou Y., Peng Y., Mao Q.Q. et al. Casticin induces caspase-mediated apoptosis via activation of mitochondrial pathway and upregulation of DR5 in human lung cancer cells. Asian Pac J Trop Med 2013;6(5): 372–8. DOI: 10.1016/S1995-7645(13)60041-3</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Kikuchi H., Yuan B., Nishimura Y. et al. Cytotoxicity of Vitex agnus-castus fruit extract and its major component, casticin, correlates with differentiation status in leukemia cell lines. Int J Oncol 2013;43(6):1976–84. DOI: 10.3892/ijo.2013.2133</mixed-citation><mixed-citation xml:lang="ru">Kikuchi H., Yuan B., Nishimura Y. et al. Cytotoxicity of Vitex agnus-castus fruit extract and its major component, casticin, correlates with differentiation status in leukemia cell lines. Int J Oncol 2013;43(6):1976–84. DOI: 10.3892/ijo.2013.2133</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><mixed-citation>Li W.X., Cui C.B., Cai B. et al. Flavonoids from Vitex trifolia L. inhibit cell cycle progression at G2/M phase and induce apoptosis in mammalian cancer cells. J Asian Nat Prod Res 2005;7(4):615– 26. DOI: 10.1080/10286020310001625085</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Chan E.W.C., Wong S.K., Chan H.T.J. Casticin from Vitex species: a short review on its anticancer and anti-inflammatory properties Integr Med 2018;16(3):147–52. DOI: 10.1016/j.joim.2018.03.001</mixed-citation></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Ramchandani S., Naz I., Lee J.H. et al. An overview of the potential antineoplastic effects of casticin molecules. Molecules 2020;25(6):1287. DOI: 10.3390/molecules25061287</mixed-citation><mixed-citation xml:lang="ru">Ramchandani S., Naz I., Lee J.H. et al. An overview of the potential antineoplastic effects of casticin molecules. Molecules 2020;25(6):1287. DOI: 10.3390/molecules25061287</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Jiang L., Cao X., Cao J. et al. Casticin induces ovarian cancer cell apoptosis by repressing FoxM1 through the activation of FOXO3a. Oncol Lett 2013;5;1605–10. DOI: 10.3892/ol.2013. 1258</mixed-citation><mixed-citation xml:lang="ru">Jiang L., Cao X., Cao J. et al. Casticin induces ovarian cancer cell apoptosis by repressing FoxM1 through the activation of FOXO3a. Oncol Lett 2013;5;1605–10. DOI: 10.3892/ol.2013. 1258</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><mixed-citation>Bischoff-Kont I., Brabenec L., Ingelfinger R. BNO1095, a standardized dry extract from the fruits of Vitex agnus-castus, impairs angiogenesis-related endothelial cellsfunction in vitro. Planta Med 2021;87:611–9. DOI: 1055/а-1351-1038</mixed-citation></ref></ref-list></back></article>
